表皮生长因子受体显像剂 18 F-FEA-Erlotinib的自动化合成

Translated title of the contribution: Automated synthesis of EGFR imaging tracer 18 F-FEA-Erlotinib

Shun Huang, Yanjiang Han, Kongzhen Hu, Meng Wang, Penghui Sun, Hubing Wu, Quanshi Wang, Suqing Zhao, Xi Zheng

Research output: Contribution to journalArticle

Abstract

Background: PET imaging of 11 C-Erlotinib was used to distinguish responders from nonresponders in the targeted therapy for non-small cell lung cancer (NSCLC). However, the short half-life (20 min) of carbon-11 limits its widespread use as a tool for community-based diagnostic screening and therapeutic evaluation. We proposed that this shortcoming could be overcome by the development of a fluorine-18 (half-life is 109 min) labeled Erlotinib. Purpose: We automatically labelled Erlotinib with flurorine-18 through the "click chemistry" and explored its preliminary evaluation. Methods: 18 F-FEA-Erlotinib was synthesized from 2- 18 F-fluorine azide ethane ( 18 F-FEA), a radiochemical intermediate, through the "click chemistry" in the PET-MF-2V-IT-I synthesis module and purified by semi-preparative high performance liquid chromatography (HPLC). The stability of 18 F-FEA-Erlotinib was performed in phosphate buffer saline (PBS) and fetal bovine serum (FBS). The octanol/water partition coefficient and routine quality control were tested. Results: 18 F-FEA-Erlotinib was achieved within 70 min with (54±2)% radiochemical yield (decay corrected), an average specific activity over 200MBq∙μmol -1 , and over 99% radiochemical purity. The logP of 18 F-FEA-Erlotinib was 2.36±0.01. The final injection was free of bacteria and pyrogen, and the K 2.2.2 concentration was lower than 10 mg∙L -1 . Conclusion: 18 F-FEA-Erlotinib was easy to be prepared by the "click chemistry" in an automatic synthesis system. 18 F-FEA-Erlotinib has a similar lipophilicity to Erlotinib and a high metabolic stability in vitro.

Original languageChinese
Article number010301
JournalHe Jishu/Nuclear Techniques
Volume41
Issue number1
DOIs
StatePublished - Jan 10 2018
Externally publishedYes

Fingerprint

Fluorine
Ethane
tracers
fluorine
ethane
Imaging techniques
Finite element method
synthesis
chemistry
half life
pyrogen
transponders
evaluation
liquid chromatography
High performance liquid chromatography
quality control
serums
lungs
bacteria
Quality control

All Science Journal Classification (ASJC) codes

  • Radiation
  • Nuclear and High Energy Physics
  • Nuclear Energy and Engineering

Cite this

Huang, Shun ; Han, Yanjiang ; Hu, Kongzhen ; Wang, Meng ; Sun, Penghui ; Wu, Hubing ; Wang, Quanshi ; Zhao, Suqing ; Zheng, Xi. / 表皮生长因子受体显像剂 18 F-FEA-Erlotinib的自动化合成 In: He Jishu/Nuclear Techniques. 2018 ; Vol. 41, No. 1.
@article{b4f12be1bb834d5083ad15b08fc5d353,
title = "表皮生长因子受体显像剂 18 F-FEA-Erlotinib的自动化合成",
abstract = "Background: PET imaging of 11 C-Erlotinib was used to distinguish responders from nonresponders in the targeted therapy for non-small cell lung cancer (NSCLC). However, the short half-life (20 min) of carbon-11 limits its widespread use as a tool for community-based diagnostic screening and therapeutic evaluation. We proposed that this shortcoming could be overcome by the development of a fluorine-18 (half-life is 109 min) labeled Erlotinib. Purpose: We automatically labelled Erlotinib with flurorine-18 through the {"}click chemistry{"} and explored its preliminary evaluation. Methods: 18 F-FEA-Erlotinib was synthesized from 2- 18 F-fluorine azide ethane ( 18 F-FEA), a radiochemical intermediate, through the {"}click chemistry{"} in the PET-MF-2V-IT-I synthesis module and purified by semi-preparative high performance liquid chromatography (HPLC). The stability of 18 F-FEA-Erlotinib was performed in phosphate buffer saline (PBS) and fetal bovine serum (FBS). The octanol/water partition coefficient and routine quality control were tested. Results: 18 F-FEA-Erlotinib was achieved within 70 min with (54±2){\%} radiochemical yield (decay corrected), an average specific activity over 200MBq∙μmol -1 , and over 99{\%} radiochemical purity. The logP of 18 F-FEA-Erlotinib was 2.36±0.01. The final injection was free of bacteria and pyrogen, and the K 2.2.2 concentration was lower than 10 mg∙L -1 . Conclusion: 18 F-FEA-Erlotinib was easy to be prepared by the {"}click chemistry{"} in an automatic synthesis system. 18 F-FEA-Erlotinib has a similar lipophilicity to Erlotinib and a high metabolic stability in vitro.",
author = "Shun Huang and Yanjiang Han and Kongzhen Hu and Meng Wang and Penghui Sun and Hubing Wu and Quanshi Wang and Suqing Zhao and Xi Zheng",
year = "2018",
month = "1",
day = "10",
doi = "10.11889/j.0253-3219.2018.hjs.41.010301",
language = "Chinese",
volume = "41",
journal = "He Jishu/Nuclear Techniques",
issn = "0253-3219",
publisher = "Science Press",
number = "1",

}

表皮生长因子受体显像剂 18 F-FEA-Erlotinib的自动化合成 . / Huang, Shun; Han, Yanjiang; Hu, Kongzhen; Wang, Meng; Sun, Penghui; Wu, Hubing; Wang, Quanshi; Zhao, Suqing; Zheng, Xi.

In: He Jishu/Nuclear Techniques, Vol. 41, No. 1, 010301, 10.01.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - 表皮生长因子受体显像剂 18 F-FEA-Erlotinib的自动化合成

AU - Huang, Shun

AU - Han, Yanjiang

AU - Hu, Kongzhen

AU - Wang, Meng

AU - Sun, Penghui

AU - Wu, Hubing

AU - Wang, Quanshi

AU - Zhao, Suqing

AU - Zheng, Xi

PY - 2018/1/10

Y1 - 2018/1/10

N2 - Background: PET imaging of 11 C-Erlotinib was used to distinguish responders from nonresponders in the targeted therapy for non-small cell lung cancer (NSCLC). However, the short half-life (20 min) of carbon-11 limits its widespread use as a tool for community-based diagnostic screening and therapeutic evaluation. We proposed that this shortcoming could be overcome by the development of a fluorine-18 (half-life is 109 min) labeled Erlotinib. Purpose: We automatically labelled Erlotinib with flurorine-18 through the "click chemistry" and explored its preliminary evaluation. Methods: 18 F-FEA-Erlotinib was synthesized from 2- 18 F-fluorine azide ethane ( 18 F-FEA), a radiochemical intermediate, through the "click chemistry" in the PET-MF-2V-IT-I synthesis module and purified by semi-preparative high performance liquid chromatography (HPLC). The stability of 18 F-FEA-Erlotinib was performed in phosphate buffer saline (PBS) and fetal bovine serum (FBS). The octanol/water partition coefficient and routine quality control were tested. Results: 18 F-FEA-Erlotinib was achieved within 70 min with (54±2)% radiochemical yield (decay corrected), an average specific activity over 200MBq∙μmol -1 , and over 99% radiochemical purity. The logP of 18 F-FEA-Erlotinib was 2.36±0.01. The final injection was free of bacteria and pyrogen, and the K 2.2.2 concentration was lower than 10 mg∙L -1 . Conclusion: 18 F-FEA-Erlotinib was easy to be prepared by the "click chemistry" in an automatic synthesis system. 18 F-FEA-Erlotinib has a similar lipophilicity to Erlotinib and a high metabolic stability in vitro.

AB - Background: PET imaging of 11 C-Erlotinib was used to distinguish responders from nonresponders in the targeted therapy for non-small cell lung cancer (NSCLC). However, the short half-life (20 min) of carbon-11 limits its widespread use as a tool for community-based diagnostic screening and therapeutic evaluation. We proposed that this shortcoming could be overcome by the development of a fluorine-18 (half-life is 109 min) labeled Erlotinib. Purpose: We automatically labelled Erlotinib with flurorine-18 through the "click chemistry" and explored its preliminary evaluation. Methods: 18 F-FEA-Erlotinib was synthesized from 2- 18 F-fluorine azide ethane ( 18 F-FEA), a radiochemical intermediate, through the "click chemistry" in the PET-MF-2V-IT-I synthesis module and purified by semi-preparative high performance liquid chromatography (HPLC). The stability of 18 F-FEA-Erlotinib was performed in phosphate buffer saline (PBS) and fetal bovine serum (FBS). The octanol/water partition coefficient and routine quality control were tested. Results: 18 F-FEA-Erlotinib was achieved within 70 min with (54±2)% radiochemical yield (decay corrected), an average specific activity over 200MBq∙μmol -1 , and over 99% radiochemical purity. The logP of 18 F-FEA-Erlotinib was 2.36±0.01. The final injection was free of bacteria and pyrogen, and the K 2.2.2 concentration was lower than 10 mg∙L -1 . Conclusion: 18 F-FEA-Erlotinib was easy to be prepared by the "click chemistry" in an automatic synthesis system. 18 F-FEA-Erlotinib has a similar lipophilicity to Erlotinib and a high metabolic stability in vitro.

UR - http://www.scopus.com/inward/record.url?scp=85051787604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051787604&partnerID=8YFLogxK

U2 - 10.11889/j.0253-3219.2018.hjs.41.010301

DO - 10.11889/j.0253-3219.2018.hjs.41.010301

M3 - Article

VL - 41

JO - He Jishu/Nuclear Techniques

JF - He Jishu/Nuclear Techniques

SN - 0253-3219

IS - 1

M1 - 010301

ER -